PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 161 filers reported holding PROGENICS PHARMACEUTICALS IN in Q1 2017. The put-call ratio across all filers is 0.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $946,000 | -15.7% | 109,436 | -38.2% | 0.38% | +3.0% |
| Q3 2016 | $1,122,000 | +109.3% | 177,206 | +39.4% | 0.37% | +120.8% |
| Q2 2016 | $536,000 | -48.1% | 127,126 | -46.3% | 0.17% | -40.0% |
| Q1 2016 | $1,033,000 | -33.4% | 236,856 | -6.3% | 0.28% | -12.8% |
| Q4 2015 | $1,550,000 | +7.2% | 252,785 | 0.0% | 0.32% | +9.9% |
| Q3 2015 | $1,446,000 | -23.3% | 252,785 | 0.0% | 0.29% | -15.4% |
| Q2 2015 | $1,886,000 | -10.7% | 252,785 | -28.4% | 0.34% | -9.2% |
| Q1 2015 | $2,112,000 | +125.9% | 353,140 | +185.5% | 0.38% | +242.3% |
| Q4 2014 | $935,000 | -7.2% | 123,710 | -36.3% | 0.11% | +85.0% |
| Q3 2014 | $1,008,000 | – | 194,230 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 17,902,338 | $135,342,000 | 5.88% |
| TIGER MANAGEMENT L.L.C. | 1,288,454 | $9,741,000 | 1.91% |
| Phocas Financial Corp. | 1,047,181 | $7,917,000 | 0.69% |
| TUDOR INVESTMENT CORP ET AL | 2,370,503 | $17,921,000 | 0.62% |
| EAM Investors, LLC | 553,309 | $4,183,000 | 0.58% |
| Baker Brothers Advisors | 4,449,797 | $33,640,000 | 0.34% |
| TFS CAPITAL LLC | 463,740 | $3,506,000 | 0.33% |
| FEDERATED HERMES, INC. | 13,508,290 | $102,123,000 | 0.32% |
| Rotella Capital Management, Inc. | 36,473 | $276,000 | 0.24% |
| OXFORD ASSET MANAGEMENT LLP | 1,103,848 | $8,351,000 | 0.18% |